Opioid Dependence During Pregnancy



Opioid Dependence During Pregnancy

Michelle Lofwall, M.D.

University of Kentucky

(slide 1)

©AMSP 2009

I. Introduction

A. Opioid dependence during pregnancy (preg) challenging to treat (slide 2)

1. Doctors (medical student & resident) inadequately trained 1

2. Medical & legal system prejudice

a. ~25% OB/peds/family practice docs → drug use in preg warrants incarceration 2

b. Survey of new mothers report that nurses:

i. Treat them negatively when find out test + for illicit drugs 3

ii. ↓ Attention to them when find out test + for illicit drugs 3

c. Legal charges brought against preg ♀ who use illicit drugs

i. Charges include fetal murder/manslaughter, illegal drug delivery & trafficking (via umbilical cord), & child abuse 4

ii. Fear of prosecution can deter ♀ from seeking treatment (rx) 2

iii. Often highly publicized & may scare doctors from offering rx 4

3. Doctors may need to report drug use in preg to various state agencies 5

4. Overall, problems establishing therapeutic doctor-patient alliance 5

B. What you need to know about opioid dependence during preg (slide 3)

1. Understand punishing preg ♀ for using illicits ≠ effective deterrent

a. Criminal prosecution hasn’t ↓opioid use in preg 6, 7

b. Comprehensive medical & psychosocial rx helps mom & baby 8, 9

i. 3-fold ↓ in mothers’ opiate use 10

ii. Initiates & improves attendance to prenatal care 9, 11

iii. 3-fold ↓ risk of low birth weight baby (LBW: attn than abuse) 8, 15

E. Have now completed Defns section. Now discuss causes, course, prevelance & comorbities section. (slide 8)

III. Causes, course, prevalence & comorbidities among opioid dependent mothers

A. Etiology of opioid abuse/dependence = 50% genes & 50% environment 16 (slide 9)

1. Role of genes vs. environmental factors determined by twin studies

2. Female twins evaluated to determine: 16

a. Genetic similarity: identical twins =100% same vs. fraternal = 50% same

b. Environment: shared and non-shared

3. Environmental factors that contribute to etiology include: 17

a. Availability & peer use

b. Drug-using sexual partner

c. History of victimization (e.g., childhood physical/sexual abuse)

B. Course of opioid abuse/dependence = chronic, relapsing with ↑ mortality 18 (slide 10)

1. >50% preg opioid dependent ♀ relapse 19-21

2. Opioid use starts before pregnancy for >90% of preg opioid dep ♀ in rx 19, 20, 22

3. Mortality: 20x vs. age-matched non-sub abuse/dependent (note: mostly ♂ studied) 23, 24

C. Prevalence of opioid abuse/dependence during preg unknown

1. Epidemiologic data rely 1° on self-report of opioid use

2. U.S. National Survey on Drug Use and Health: annual cross-sectional survey 7

a. Preg ♀ age 15-44 yrs evaluated

b. All are community dwelling (ø hospital, prison, homeless without shelter)

c. 1% of preg ♀ self-report current opioid use during preg vs. ~3% of non-preg ♀

d. 1° opioids used = prescription pain pills (not heroin)

e. Overall, low prevalence of opioid use in preg

3. How accurate are self-reports? (slide 11)

a. Study tested meconium (newborn stool) vs. maternal self-report of drug use 6

i. Meconium opiate + : 8.7% vs. maternal self-report opiate use: 1%

ii. Self-report underestimates opioid use

b. Stigma/shame/fear ↓ self-report 5

c. Message=cannot rely only on self-report to detect illicit opioid use

D. Preg opioid dependent ♀ use other drugs (slide 12)

1. 2 most commonly used other substances = cigarettes & cocaine

a. 90% smoke cigarettes, 25, 26 which are independently associated with :

i. ↑ Spontaneous abortion & stillbirths 27

ii. ↑ Pre-term birth (10% use cocaine, 28-30 which is independently associated with:

i. ↑ Placental abruption 31

ii. ↑ Pre-term birth 31

2. Makes difficult determine what effects 2° to maternal opioid use

E. Preg opioid dependent ♀ have non-substance psychiatric dx (slide 12)

1. Psychiatric dxs in non-preg opioid dep ♀ in treatment (Note: limited data in preg ♀)

a. >10% current non-substance Axis I DSM-IV dx (mood & anxiety do=#1) 32, 33

b. ~25% with current personality disorder (Axis II) DSM-IV dx 32

1. Non-substance psychiatric dxs associated with adverse preg outcomes

a. E.g.,: mood disorders ↑ incidence of low birth weight, ↓fetal growth 34

b. Makes difficult determine what effects 2° to maternal opioid use

F. Preg opioid dependent ♀ have complex social problems (slide 13)

1. Poor psychosocial supports (e.g., >50% are single moms) 35-37

2. Low socioeconomic status (e.g., receiving public health care) 9

2. > 50% unemployed 35, 36

4. > 25% history of physical/sexual abuse 8, 36, 38

5. These social problems adversely affect pregnancy 8

a. ↓ Access to prenatal care

b. ↓ Adherence with prenatal appt

c. Direct physical harm to mom/fetus (e.g., due to physical abuse)

6. Makes difficult determine what effects 2° to maternal opioid use

G. Preg opioid dependent ♀ engage in risky behaviors (slide 14)

1. Sharing needles/drug paraphernalia, dealing drugs, unprotected sex, prostitution

2. ↑ risk for infectious diseases, cellulitis (infection of skin), physical trauma, homicide

3. Infections in mom can be harmful to fetus: 39

a. Infxn can spread to placenta/amniotic fluid causing chorioamnionitis

b. Mom’s immune response (ex: IL-6, TNF, prostaglandines) exacerbate situation

c. These can then induce:

i. Premature uterine contractions, labor & delivery

ii. Breakdown of fetal membranes & spontanteous abortion

H. Now completed Causes, course, prevalence & comorbities. Major points are: (slide 15)

1. Etiology of opioid abuse/dependence = genes & environment

2. Serious psychosocial & medical problem, often chronic in nature

3. Many comorbidities associated with opioid abuse/depend in preg

4. These comorbidities independently ↑ risk for harm to mother & baby

I. Medical complications will be discussed next

IV. Medical complications of opioid dependence on mom, fetus & newborn

A. Medical problems in mother and fetus 40, 41 (slide 16)

1. Multifactorial etiology (as discussed above because of all comorbidities)

2. Infectious diseases include (but not limited to):

a. HIV: Major concern given risk of IV drug use (IVDU) & unprotected sex

i. ~If mom HIV + → 25% transmit to baby if untreated 8

ii. If mom receives HIV rx → 2/3 of IVDU 42

i. ~5% transmit to fetus (higher if mom also HIV +) 43, 44

ii. No way yet to decrease transmission rate (e.g., C-section does not help) 43, 44

iii. Mom can breastfeed if she is Hep C +

iv. Hepatitis C most common reason for liver transplant request in U.S.

c. Endocarditis (infection of heart valve) among IVDU

i. Often right-sided involving tricuspid valve 42

ii. Can lead to heart failure → inadequate oxygenated blood supply to fetus

iii. 10% mortality in adults 42

3. Nutritional deficiencies 40, 41

a. Cause often poor diet & not taking prenatal iron-fortified vitamins

b. Iron-deficiency anemia in preg (prevalence ~25%) independently associated with:45

i. Preterm birth

ii. Low birth weight

iii. Small for gestational age

B. Fetal hypoxia (low oxygen) = major concern for fetus in opioid depend moms (slide 17)

1. Many causes (ex: cocaine, smoking) & fluctuating maternal intake of opioids

2. Opioids cross placenta 8

3. Maternal opioid use pattern: use a lot, stop, withdrawal, use again causes:

a. Changing opioid concentrations (conc) for fetus = unstable environment

b. Repeated cycles of fetal opioid intoxication & withdrawal 39

c. Constant conc. mitigate problem (why methadone rx helps – discuss more later)

4. Hypoxia can lead to: 39

a. Spontaneous abortion

b. Placental insufficiency

c. Hypertensive emergencies

d. Pre-term labor

e. Poor fetal growth

C. Medical problems in newborn 32, 40, 41, 46 (slide 18)

1. ~50% low birth weight (vs. < 20% in methadone maintenance rx)

2. Death (no good current data on rates)

3. Meconium aspiration (no good current data on rates)

4. ~ 10% microcephaly (small head): 0.8 cm smaller than nondrug-exposed neonates8, 13

5. HIV/hep C infection passed from mom (discussed above)

6. Neonatal abstinence syndrome

D. Neonatal abstinence syndrome (NAS) = opioid withdrawal in newborn (slide 19)

1. Distressing for med stud/mom to see; why mom’s say baby born “addicted”

2. Dx based on signs from 4 systems 8 (slide 20)

a. CNS excitability: seizure, tremors, hypertonia, poor sleep, high pitched cry

b. Autonomic nervous system ↑: sweating, sneezing, tearing, hyperthermia

c. GI system: uncoordinated suck/swallow → feed difficult, vomit, diarrhea

d. Respiratory distress: ↑ secretions, hyperpnea (↑ RR), cyanosis, apnea

e. Can be deadly if not recognized & treated

3. Time course of NAS (slide 21)

a. Multiple factors affect onset & duration: 8

i. Half-life (T ½) of opioid (the shorter the T1/2 the sooner NAS develops)

ii. Fetal opioid storage (if stored prolongs time to development of NAS)

iii. Rate of fetal metabolism & excretion (faster = more abrupt NAS)

b. Heroin

i. Has short T ½ (5 minutes) & not stored by fetus 8

ii. Typically see NAS develop 4-24 hrs after birth 8

b. Methadone

i. Has longer T ½ (27 hrs) & stored by fetal lung/liver/spleen 8

ii. Typically see NAS develop 24-72 hrs after birth 8

d. Duration of NAS: highly variable from 6 days to 8 weeks

4. Risk factors: (slide 21)

a. Maternal opioid depend: ~70% of babies will have NAS 47

b. Smoking 1ppd vs. ½ ppd: ↑ peak NAS severity x2 48

c. Prematurity ↓ severity of NAS 49, 50

5. NAS treatment = medication if severe & supportive interventions always (slide 22)

a. Supportive: swaddle, quiet spaces, freq feeds, suction excretions 41

b. Med: tincture of opium (TOC) recommended by American Academy of Pediatrics51

i. TOC has many ingredients (e.g., morphine, codeine)

ii. TOC concentration =10mg/mL but is typically diluted 25-fold

iii. 25-fold dilution results in 0.4 mg/mL of morphine

iv. Starting dose = 2 drops/kg or 1 mL/kg every 4 hrs

v. Dose increased by 2 drops/kg every 4 hrs as needed to control withdrawal

c. ~60% of babies with NAS require medication 47

d. Treatment of severe NAS is life-saving

E. Have now completed Medical Complications section. Major points are: (slide 23)

1. Many serious medical problems in mom/fetus/neonate

2. Repeated opioid withdrawal & intox causes unstable fetal environment & hypoxia

3. Opioid withdrawal can be deadly in neonate, but it’s treatable & rx = life-saving

F. Treatment of opioid dependence during pregnancy discussed next

V. Treatment of opioid dependence during pregnancy

A. 4 treatments will be reviewed (slide 24)

1. Psychosocial interventions/counseling

2. Methadone maintenance (MM) rx

3. Methadone withdrawal

4. Buprenorphine maintenance

B. Psychosocial interventions/counseling (slide 25)

1. Essential component/cornerstone of rx for all substance use disorders

2. Counseling: individual, group, 12-step oriented (ex: Narcotics Anonymous)

3. Build therapeutic alliance 9

a. Recognize ♀’s courage in ask for help

b. Facilitate rx entry: remove barriers

i. Flexible scheduling

ii. Timely – no long waiting lists

iii. Emphathic treatment providers

iv. Allow children to come

4. What to do when pt is demanding & resistant? 9

a. View as expected & normal behavior

b. Think of as challenge & discuss with other rx team members

c. Don’t give up, be positive & encouraging

d. Behavior & attitudes change over time

5. Make complete assessment of all rx needs 9, 40

a. Assess for psychiatric problems & treat

b. Assess for medical problems & treat

c. Assess social situation & assist

i. Living situation – homeless, domestic violence, partner using drugs?

ii. Employment status – job skills training need?

iii. Need to apply for public health care?

C. Methadone maintenance (MM): standard of care for opioid depend in preg 40 (slide 26)

1. Methadone = synthetic opioid agonist with long T ½ (27 hrs)14

2. 1972 FDA-approved for opioid dependence rx

3. Methadone & the law 52

a. Only federally licensed MM clinics can prescribe

b. Must be at least 18 yr old

c. If < 18 yrs old need:

i. Parental consent &

ii. Failed 2 detoxification or drug-free treatments

d. Must >1 yr opioid dependent & evidence of depend (preg is exception)

e. Must come daily to get medicated for 1st 90 days

i. Supervised dosing helps to ensure medication taken as prescribed

ii. ↓ risk of diversion/misuse of medication by injection

iii. Opportunity deliver on-site psychosocial/med services

4. Goals of MM:

a. Mother 40 (slide 27)

i. Prevent opioid withdrawal

ii. Stop illicit opioid & all illicit drug, alcohol & nicotine use

iii. Assist with psychosocial problems

iv. Treat comorbid medical & psychiatric problems

v. Form supportive abstinent network

vi. Engage in prenatal care & other medical/psychiatric care

vii. Develop parenting skills

viii. Notice: goals = more than drug abstinence b/c probs > drug use

b. Fetus/neonate 40 (slide 28)

i. Stabilize intrauterine environment

ii. Stop fetal cycles of opioid withdrawal/intoxication

iii. Deliver term, healthy neonate

iv. Promote + maternal bonding

5. Achieved by following components of rx: 40 (slide 29)

a. Multidisciplinary team working together

i. Social workers & counselors

ii. Physician at methadone clinic

iii. OB

iv. Anesthesiologist for pain management during delivery/post-partum

v. Other specialities as needed (Infectious diseases, internist, psychiatrist)

b. Individual & group counseling

i. Identify & prioritize rx needs

ii. Similar as in psychosocial rx discussed already

iii. Non-confrontational approach

iv. Amount of counseling + affects drug use 53

c. Parenting classes

d. Daily oral methadone administration

i. Only legal if through licensed methadone clinic

ii. Initial doses 30 mg usually, 40 mg maximum on 1st day 52

iii. Typical maintenance doses: at least 50 mg daily 52

iv. Dose must be individualized – no single “right” dose for everyone

v. Dose may change with trimesters as gain more total body water

vi. Effective dose = suppress withdrawal & block + illicit opioid effects if use

e. Notice: methadone only 1 part of MM rx

6. Benefits of MM rx vs. no rx 8, 9 (slide 30)

a. 3-fold ↓ in mothers’ opiate use 10

b. Initiates & improves attendance to prenatal care 9, 11

c. 3-fold ↓ risk of low birth weight baby 12

d. If mother HIV + & accepts rx, ↓ perinatal transmission to < 2% 8

e. Mother ~2x more likely retain custody/parenting role in childs’ 1st year of life 13

7. Limitations of MM (slide 31)

a. Limited MM availability - some states 0 or 1 clinic 40

b. Limited patient acceptance: stigma, daily visits, fear baby born “addicted”

c. Does not reduce risk for NAS

8. Developmental effects for children prenatally exposed to MM 8, 13, 54-57

a. Multiple factors influence - environment, parenting (not just the drug)

b. Mental & motor fxn within normal range

c. Possible fine motor skill probs (but not different from untreated drug-exposed)

D. Methadone-assisted opioid withdrawal (slide 32)

1. Recommended rx early 1970’s until case-reports of fetal deaths appeared 58

2. Now utilized when MM is unavailable or refused 11

3. Goals of rx:

a. Prevent & ↓ severity of op withdrawal to mom/fetus

b. Achieve opioid-free state in mother/fetus

c. No NAS

4. Achieved by following components: (slide 33)

a. Inpatient hospital admission with multi-disciplinary team

b. Stabilize on methadone to alleviate withdrawal

c. Taper methadone dose while OB monitors fetus for evidence of distress

i. No specified amount of time

ii. If fetal distress emerges – prolong taper/adjust dose to relieve withdrawal

iii. Tapers completed safely within 3 and 7 days at specialty inpatient rx units 11

d. Discharge patient from hospital

e. Cont’d treatment aimed at maintaining opioid abstinence

5. Outcomes (slide 34)

a. 40-100% preg ♀ relapse 19-21 – why such high relapse rate?

i. Problem not only about physical dependence & withdrawal

ii. Complicated psychosocial problem – remember the comorbidity discussed

b. MM vs methadone detox study - detox resulted in: 11

i. 2x ↑ drug + urine at time of delivery

ii. 5x ↓ days retained in substance abuse treatment

iii. 6 fewer OB appts attended

iv. No diff in NAS or other fetal/neonatal outcomes

E. Buprenorphine - potential future rx for opioid depend in pregnancy (slide 35)

1. 2002 FDA-approved for trx of opioid dependence, but not approved in preg

2. Pharmacology 59

a. Partial opioid agonist = not as strong as full op agonist

b. Enhanced safety profile (Schedule III) - ceiling effect on respiratory depression

c. Sublingual tablet b/c poor gut absorption

d. T ½ = 37 hrs – allows for daily or alternate day dosing

3. Buprenorphine & the law 59 (slide 36)

a. Drug Abuse Treatment Act of 2000 allows it to be prescribed in a doctor’s office

b. Doctor must be qualified to prescribe:

i. Most commonly done by completing a 8 hr CME about bup

ii. Must get special DEA X # before prescribing

4. Potential office-based treatment advantages over MM clinic 59, 60

a. ↑ patient acceptability

b. ↑ patient anonymity

c. ↓ stigma

d. ↑ availability of rx

5. Research shows as good as methadone on several outcomes 9, 28, 30, 61-65

a. Maternal illicit opioid use

b. Maternal attendance at prenatal OB visits

c. Maternal treatment retention

d. Neonatal birth weight

e. Rate of NAS

f. Severity of NAS

g. Neonatal days in ICU

6. Large NIH multi-site clinical trial of bup vs. methadone in preg underway

F. Now completed rx review. Summary: (slide 37)

1. MM is current standard of care

2. Improves maternal & fetal outcomes

3. MM = more than just methadone administration

4. Must treat all psychosocial aspects, too

5. Overall, golden opportunity to make + impact

References:

1. Yoast RA, Wilford BB, Hayashi SW. Encouraging physicians to screen for and intervene in substance use disorders: obstacles and strategies for change. J Addict Dis. 2008;27:77-97.

2. Abel EL, Kruger M. Physician attitudes concerning legal coercion of pregnant alcohol and drug abusers. Am J Obstet Gynecol. 2002;186:768-772.

3. Selleck CS, Redding BA. Knowledge and attitudes of registered nurses toward perinatal substance abuse. J Obstet Gynecol Neonatal Nurs. 1998;27:70-77.

4. Harris LH, Paltrow L. MSJAMA. The status of pregnant women and fetuses in US criminal law. JAMA. 2003;289:1697-1699.

5. Roberts LW, Dunn LB. Ethical considerations in caring for women with substance use disorders. Obstet Gynecol Clin North Am. 2003;30:559-582.

6. Pichini S, Puig C, Zuccaro P, et al. Assessment of exposure to opiates and cocaine during pregnancy in a Mediterranean city: preliminary results of the "Meconium Project". Forensic Sci Int. 2005;153:59-65.

7. Substance Abuse and Mental Health Services Administration (SAMHSA). National Survey on Drug Use and Health: Detailed Tables 7.69 and 7.70 from 2004-5 & 2006-7.

8. Finnegan L, Kandall S. Maternal and neonatal effects of alcohol and drugs. In: Lowinson J, Ruiz P, Milman R, Langrod J, eds. Substance Abuse: A comprehensive textbook. Fourth ed. Philadelphia: Lippincott Williams and Wilkins; 2005:805-839.

9. Jones HE, Martin PR, Heil SH, et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat. 2008;35:245-259.

10. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003;2:1-17

11. Jones HE, O'Grady KE, Malfi D, Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict. 2008;17:372-386.

12. Hulse GK, Milne E, English DR, Holman CD. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction. 1997;92:1571-1579.

13. Wilson GS, Desmond MM, Wait RB. Follow-up of methadone-treated and untreated narcotic-dependent women and their infants: health, developmental, and social implications. J Pediatr. 1981;98:716-722.

14. Gutstein H, Akil H. Opioid Analgesics. In: Hardman J, Limbird L, Gilman A, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th edition. New York: McGraw-Hill 2001:569-619.

15. Finnegan LP, Reeser DS, Connaughton JF, Jr. The effects of maternal drug dependence on neonatal mortality. Drug Alcohol Depend. 1977;2:131-140.

16. Kendler KS, Karkowski L, Prescott CA. Hallucinogen, opiate, sedative and stimulant use and abuse in a population-based sample of female twins. Acta Psychiatr Scand. 1999;99:368-376.

17. Zilberman M, Blume S. Drugs and Women. In: Lowinson J, Ruiz P, Milman R, Langrod J, eds. Substance Abuse: A comprehensive textbook. Fourth ed. Philadephia: Lippincott Williams and Wilkins; 2005:1064-1075.

18. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689-1695.

19. Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD, Jr. Opioid detoxification in pregnancy. Obstet Gynecol. 1998;92:854-858.

20. Luty J, Nikolaou V, Bearn J. Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat. 2003;24:363-367.

21. Maas U, Kattner E, Weingart-Jesse B, Schafer A, Obladen M. Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. J Perinat Med. 1990;18:111-118.

22. Jansson LM, Svikis DS, Velez M, Fitzgerald E, Jones HE. The impact of managed care on drug-dependent pregnant and postpartum women and their children. Subst Use Misuse. 2007;42:961-974.

23. Neumark YD, Van Etten ML, Anthony JC. "Drug dependence" and death: survival analysis of the Baltimore ECA sample from 1981 to 1995. Subst Use Misuse. 2000;35:313-327.

24. Hser YI, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001;58:503-508.

25. Svikis DS, Lee JH, Haug NA, Stitzer ML. Attendance incentives for outpatient treatment: effects in methadone- and nonmethadone-maintained pregnant drug dependent women. Drug Alcohol Depend. 1997;48:33-41.

26. Tuten M, Jones HE, Svikis DS. Comparing homeless and domiciled pregnant substance dependent women on psychosocial characteristics and treatment outcomes. Drug Alcohol Depend. 2003;69:95-99.

27. Rogers JM. Tobacco and pregnancy: overview of exposures and effects. Birth Defects Res C Embryo Today. 2008;84:1-15.

28. Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction. 2006;101:275-281.

29. Heil SH, Sigmon SC, Jones HE, Wagner M. Comparison of characteristics of opioid-using pregnant women in rural and urban settings. Am J Drug Alcohol Abuse. 2008;34:463-471.

30. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79:1-10.

31. Addis A, Moretti ME, Ahmed Syed F, Einarson TR, Koren G. Fetal effects of cocaine: an updated meta-analysis. Reprod Toxicol. 2001;15:341-369.

32. Brooner RK, King VL, Kidorf M, Schmidt CW, Jr., Bigelow GE. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54:71-80.

33. Fitzsimons HE, Tuten M, Vaidya V, Jones HE. Mood disorders affect drug treatment success of drug-dependent pregnant women. J Subst Abuse Treat. 2007;32:19-25.

34. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists. Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008;111:1001-1020.

35. Kissin WB, Svikis DS, Morgan GD, Haug NA. Characterizing pregnant drug-dependent women in treatment and their children. J Subst Abuse Treat. 2001;21:27-34.

36. Moylan PL, Jones HE, Haug NA, Kissin WB, Svikis DS. Clinical and psychosocial characteristics of substance-dependent pregnant women with and without PTSD. Addict Behav. 2001;26:469-474.

37. Svikis DS, Golden AS, Huggins GR, et al. Cost-effectiveness of treatment for drug-abusing pregnant women. Drug Alcohol Depend. 1997;45:105-113.

38. Jones HE, Tuten M, Keyser-Marcus L, Svikis DS. Specialty treatment for women. In: Strain EC, Stitzer ML, eds. The treatment of opioid dependence. Baltimore: Johns Hopkins University Press; 2006:455-484.

39. Helmbrecht G, Thiagarajah S. Management of Addiction Disorders in Pregnancy. J Addict Med. 2008;2:1-16.

40. Substance abuse and mental health services administration (SAMHSA). Medication-Assisted Treatment in Opioid Treatment Programs: A Treatment Improvement Protocol (TIP) 43. DHHS Publication No. (SMA) 054048; 2005:211-224.

41. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am. 1998;25:139-151.

42. Gourevitch M, Arnsten J. Medical complications of drug use. In: Lowinson J, Ruiz P, Millman R, Langrod J, eds. Substance Abuse: A comprehensive textbook. Fourth ed. Philadelphia: Lippincott Williams and Wilkins; 2005:840-862.

43. McMenamin MB, Jackson AD, Lambert J, et al. Obstetric management of hepatitis C-positive mothers: analysis of vertical transmission in 559 mother-infant pairs. Am J Obstet Gynecol. 2008;199:311-315.

44. Gonik B. The role of obstetrician/gynecologists in the management of hepatitis C virus infection. Infect Dis Obstet Gynecol. 2008;1-7.

45. Milman N. Prepartum anaemia: prevention and treatment. Ann Hematol. 2008;87:949-959.

46. Sinha C, Ohadike P, Carrick P, Pairaudeau P, Armstrong D, Lindow SW. Neonatal outcome following maternal opiate use in late pregnancy. Int J Gynaecol Obstet. 2001;74:241-246.

47. Winklbaur B, Jung E, Fischer G. Opioid dependence and pregnancy. Curr Opin Psychiatry. 2008;21:255-259.

48. Choo RE, Huestis MA, Schroeder JR, Shin AS, Jones HE. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend. 2004;75:253-260.

49. Doberczak TM, Kandall SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr. 1991;118:933-937.

50. Dysart K, Hsieh HC, Kaltenbach K, Greenspan JS. Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome. J Perinat Med. 2007;35:344-346.

51. Neonatal drug withdrawal. American Academy of Pediatrics Committee on Drugs. Pediatrics. 1998;101:1079-1088.

52. Lowinson J, Marion I, Joseph H, et al. Methadone Maintenance. In: Lowinson J, Ruiz P, Millman R, Langrod J, eds. Substance Abuse: A Comprehensive Textbook. Fourth ed. Philadelphia: Lippincott Williams and Wilkins; 2005:616-633.

53. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269:1953-1959.

54. Kaltenbach KA, Finnegan LP. Prenatal narcotic exposure: perinatal and developmental effects. Neurotoxicology. 1989;10:597-604.

55. Kaltenbach K, Finnegan LP. Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehav Toxicol Teratol. 1986;8:353-355.

56. Kaltenbach KA. Effects of in-utero opiate exposure: new paradigms for old questions. Drug Alcohol Depend. 1994;36:83-87.

57. Messinger DS, Bauer CR, Das A, et al. The maternal lifestyle study: cognitive, motor, and behavioral outcomes of cocaine-exposed and opiate-exposed infants through three years of age. Pediatrics. 2004;113:1677-1685.

58. Rementeria JL, Nunag NN. Narcotic withdrawal in pregnancy: stillbirth incidence with a case report. Am J Obstet Gynecol. 1973;116:1152-1156.

59. Strain EC, Lofwall MR. Buprenorphine Maintenance. In: Galanter MG, Kleber HD, eds. The American Psychiatric Publishing Textbook of Substance Abuse Treatment. Fourth ed. Washington, D.C.: American Psychiatric Publishing; 2008:309-324.

60. Sullivan LE, Chawarski M, O'Connor PG, Schottenfeld RS, Fiellin DA. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend. 2005;79:113-116.

61. Ebner N, Rohrmeister K, Winklbaur B, et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend. 2007;87:131-138.

62. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008;96:69-78.

63. Minozzi S, Amato L, Vecchi S, Davoli M. Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database Syst Rev. 2008:1-24.

64. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend. 2006;82:250-257.

65. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend. 2003;70:S87-S101.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download